PHAT compared with NAMS: revenue, margins and what each company keeps, and the suppliers and customers both name

PHATPhathom Pharmaceuticals, Inc.

Mkt capRevenueRevenue

NAMSNewAmsterdam Pharma Co N.V.

Mkt capRevenueRevenue

Compare

PHATPhathom Pharmaceuticals, Inc.

NAMSNewAmsterdam Pharma Co N.V.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PHAT

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−0.96%—

Q2 FY26±28.3%▼−22.42%×0.79

Q1 FY26±17.4%▼−4.92%×0.28

Feb 26 '26±27.6%▲+10.06%×0.37

NAMS1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.6%▼−0.47%×0.04

= impliedPHAT realized, solidNAMS realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

PHATPhathom Pharmaceuticals, Inc.

5.53▼−3.66%

Mkt cap$466.6MRevenue$85MQ3 FY26Revenue$175MFY25

NAMSNewAmsterdam Pharma Co N.V.

20.17▲+0.57%

Regular sessionSep 2 '83

Mkt cap$2.4BRevenue$4MQ2 FY26Revenue$23MFY25

Compare

Regular sessionSep 2 '83

PHATPhathom Pharmaceuticals, Inc.

NAMSNewAmsterdam Pharma Co N.V.

5.53▼−3.66%

Price

20.17▲+0.57%

$466.6M

Mkt cap

$2.4B

Q3 FY26$85M

Revenue

$4MQ2 FY26

FY25$175M

Revenue

$23MFY25

PHAT5.53▼−3.66%vsNAMS20.17▲+0.57%Regular sessionSep 2 '83